- Home
- SCNI vs ENVB Comparison
SCNI vs ENVB Comparison
Compare SCNI & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- ENVB
- Stock Information
- Founded
- SCNI 2003
- ENVB 1994
- Country
- SCNI Israel
- ENVB United States
- Employees
- SCNI N/A
- ENVB N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- ENVB Health Care
- Exchange
- SCNI Nasdaq
- ENVB Nasdaq
- Market Cap
- SCNI 2.8M
- ENVB 3.3M
- IPO Year
- SCNI N/A
- ENVB N/A
- Fundamental
- Price
- SCNI $3.52
- ENVB $1.36
- Analyst Decision
- SCNI
- ENVB
- Analyst Count
- SCNI 0
- ENVB 0
- Target Price
- SCNI N/A
- ENVB N/A
- AVG Volume (30 Days)
- SCNI 20.5K
- ENVB 564.4K
- Earning Date
- SCNI 11-22-2024
- ENVB 03-25-2025
- Dividend Yield
- SCNI N/A
- ENVB N/A
- EPS Growth
- SCNI N/A
- ENVB N/A
- EPS
- SCNI 8.20
- ENVB N/A
- Revenue
- SCNI $452,000.00
- ENVB N/A
- Revenue This Year
- SCNI N/A
- ENVB N/A
- Revenue Next Year
- SCNI N/A
- ENVB N/A
- P/E Ratio
- SCNI $0.43
- ENVB N/A
- Revenue Growth
- SCNI N/A
- ENVB N/A
- 52 Week Low
- SCNI $2.23
- ENVB $1.26
- 52 Week High
- SCNI $8.92
- ENVB $657.00
- Technical
- Relative Strength Index (RSI)
- SCNI 52.91
- ENVB 16.91
- Support Level
- SCNI $3.30
- ENVB $1.26
- Resistance Level
- SCNI $3.60
- ENVB $1.70
- Average True Range (ATR)
- SCNI 0.25
- ENVB 0.17
- MACD
- SCNI -0.01
- ENVB 2.34
- Stochastic Oscillator
- SCNI 44.05
- ENVB 12.20
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.